Argenx To Buy Forte Biosciences For $2.20 Bln - ARGX News | RalliesArgenx To Buy Forte Biosciences For $2.20 Bln
A
ARGX• Argenx to acquire Forte Biosciences
- To acquire Forte Biosciences, Inc., adding first-in-class anti-CD122 antibody, FB102, to its immunology pipeline
- To buy Forte Biosciences for $77 per share in cash, equity value $2.20 billion
- Acquisition expected to close in Q3 2026
- Will be funded entirely from cash on hand
- Positive FB102 phase 1b data in celiac disease was shared last year, with phase 2 data expected in the second half of this year
